更新于：2024-12-19
Bixalomer
比沙洛姆
更新于：2024-12-19
概要
基本信息
药物类型 聚合物 |
别名 Bixalomer (JAN/USAN/INN)、AMG-223、AMG223 + [5] |
作用机制 Phosphates 调节剂(磷酸盐 调节剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2012-03-30), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C19H45ClN6O |
InChIKeyUHTZABZWCSJMDY-UHFFFAOYSA-N |
CAS号851373-13-2 |
关联
22
项与 比沙洛姆 相关的临床试验Long-Term Specified Drug Use-Results Survey in Patients With Pre-dialysis Chronic Kidney Disease
Pharmacodynamic Study of ASP1585 - Verification of Bioequivalence Between ASP1585 Granules and ASP1585 Capsules
Bixalomer versus calcium carbonate on coronary artery calcification in hemodialysis patients with hyperphosphatemia: a randomized study. - BICOLOR STUDY
100 项与 比沙洛姆 相关的临床结果
登录后查看更多信息
100 项与 比沙洛姆 相关的转化医学
登录后查看更多信息
100 项与 比沙洛姆 相关的专利（医药）
登录后查看更多信息
27
项与 比沙洛姆 相关的文献（医药）2023-01-01Blood purification
Comparative Efficacy and Acceptability of 12 Phosphorus-Lowering Drugs in Adults with Hyperphosphatemia and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis
Review
作者: Zhang, Yanbiao ; Li, Yunming ; Xiao, Hualin ; Huang, Xi ; You, Shuang ; Luo, Houli ; Li, Lingfan ; Feng, Jian ; Li, Xianhui ; Chen, Xin ; Huang, Bo ; Ai, Xiang ; Xue, Gang ; Li, Juncheng ; Dong, Hongfei
Background: Hyperphosphatemia is associated with cardiovascular morbidity and mortality in adults with chronic kidney disease (CKD). Drug therapy has an irreplaceable role in the management of hyperphosphatemia. Objectives: We aimed to compare and rank phosphorus-lowering drugs, including phosphate binder and nonphosphate binder, in hyperphosphatemia adults with CKD. Methods: We did a systematic review and frequentist random-effect network meta-analysis. We searched in PubMed, Cochrane Library, Web of Science, and Embase from inception to February 1, 2023, for randomized controlled trials of 12 phosphorus-lowering drugs in adults with hyperphosphatemia and CKD. Primary outcomes were efficacy (changes in serum phosphorus) and acceptability (treatment withdrawals due to any cause). We ranked each drug according to the value of surface under the cumulative ranking curve. We applied the Confidence in Network Meta-Analysis frameworks to rate the certainty of evidence. This study was registered with PROSPERO, number CRD42022322270. Results: We identified 2,174 citations, and of these, we included 94 trials comprising 14,459 participants and comparing 13 drugs or placebo. In terms of efficacy, except for niacinamide, all drugs lowered the level of serum phosphorus compared with placebo, with mean difference ranging between −1.61 (95% credible interval [CrI], −2.60 to −0.62) mg/dL for magnesium carbonate and −0.85 (−1.66 to −0.05) mg/dL for bixalomer. Only ferric citrate with odds ratios 0.56 (95% CrI: 0.36–0.89) was significantly associated with fewer dropouts for acceptability. Of the 94 trials, 43 (46%), 7 (7%), and 44 (47%) trials were rated as high, moderate, and low risk of bias, respectively, the certainty of the evidence was moderate to very low. Conclusions: Magnesium carbonate has the best phosphorus-lowering effect in hyperphosphatemia adults with CKD; considering efficacy and acceptability, ferric citrate shows evidence to be the most appropriate drug with or without dialysis.
2022-07-03Expert opinion on drug safety3区 · 医学
An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles
3区 · 医学
Review
作者: Ito, Hidetoshi ; Ogata, Hiroaki ; Takeshima, Akiko
INTRODUCTION:
Hyperphosphatemia is an inevitable complication for patients undergoing dialysis, as is the resulting need for treatment with phosphate binders. Currently, various phosphate binders are clinically available. In addition to their phosphate-lowering activity, individual phosphate binders have differing safety profiles and off-target actions.
AREAS COVERED:
This paper reviews the safety of phosphate binders and issues to be resolved.
EXPERT OPINION:
Calcium-based phosphate binders are well tolerated but may increase calcium overload risk. Sevelamer reduces serum cholesterol levels and exerts anti-inflammatory effects. Compared to sevelamer, bixalomer is associated with fewer gastrointestinal symptoms. Aluminum-containing binders, lanthanum carbonate, and sucroferric oxyhydroxide exhibit strong phosphate-lowering activity. Although ferric citrate reduces erythropoiesis-stimulating agents and intravenous iron doses, its use requires monitoring of iron metabolic markers to avoid overload. Occasionally, combined use of multiple phosphate binders can offer the advantages of each phosphate binder while minimizing their drawbacks; thus, this may be desirable according to individual patients' conditions and comorbidities. However, increased pill burden and nonadherence to phosphate binders emerge as new problems. We expect that novel therapeutic strategies will be developed to resolve these issues.
2021-11-01MINI-REVIEWS IN MEDICINAL CHEMISTRY3区 · 医学
The Rising Risk of Chronic Kidney Disease (CKD) and How it is Dealt
with: A Review of Current and Potential Phosphate Binders (PB)
3区 · 医学
Review
作者: Danel, Krzysztof ; Gosik, Robert
::
It is estimated that by 2040, Chronic Kidney Disease (CKD) will be the 5th main cause of
global deaths. It has been suggested that hyperphosphatemia is among the main factors leading to the
increased risk of death. This review focuses on potential and currently used Phosphate Binders (PB).
Aluminum hydroxide is presently not recommended due to potential aluminum toxicity. Calciumcontaining
phosphate binders (CCPB) can cause calcium overload, resulting in hypercalcemia and an
increased risk of cardiovascular diseases. Magnesium and calcium complexes were suggested to be as
effective as sevelamer in the reduction of serum phosphate, with the potential to slow down the process
of calcification. However, limited studies have been conducted in this area. Although sevelamer
seemed to have a positive influence on cardiovascular calcification and arterial stiffness, its influence
on mortality was unclear. Sevelamer crystal accumulation in the Gastrointestinal tract (GI) can cause
gastrointestinal bleeding. Lanthanum carbonate seemed to lower all-cause mortality and reduce the
chance of hypercalcemia, even though a deposit in the GI tract was observed. Colestilan, like sevelamer,
reduced LDL cholesterol. Sucroferric oxyhydroxide had a lower pill burden than other PBs and
it seemed to reduce serum FGF-23. Ferric citrate improved parameters that are related to anemia but
can cause iron overload. Bixalomer appeared to have fewer gastrointestinal side effects than sevelamer.
Nano-lanthanum hydroxide and SBR759 may have an interesting future as PBs. In conclusion, the
development of new PBs should also take into consideration their potential to function as protection
modifiers.
1
项与 比沙洛姆 相关的新闻（医药）2022-06-22
抗体疫苗合作细胞疗法基因疗法
100 项与 比沙洛姆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高磷血症 | 日本 | 2012-03-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肾病 | 临床3期 | 日本 | 2010-01-01 | |
| 尿毒症 | 临床3期 | 日本 | 2009-05-01 | |
| 终末期肾脏病 | 临床2期 | - | 2008-03-01 | |
| 高磷酸盐家族性肿瘤钙质沉着症 | 临床2期 | - | 2008-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 105 | 鑰簾鏇衊膚觸餘憲鹽選(鹹積積淵簾鹽鹹淵鑰鑰) = 顧鹽夢網糧鹹廠蓋網製 製蓋觸餘觸遞觸醖築鑰 (鬱糧淵醖鏇繭構淵鑰願 ) 更多 | 积极 | 2017-04-01 | |||
临床2期 | 156 | 築夢獵願範選膚艱製憲(淵構築蓋願壓網廠鑰壓) = 築觸蓋醖願窪觸餘齋糧 蓋鬱醖鬱遞製壓鹹壓願 (膚繭鏇憲淵襯鏇夢繭範 ) | - | 2014-06-01 | |||
築夢獵願範選膚艱製憲(淵構築蓋願壓網廠鑰壓) = 窪齋憲積膚觸醖淵繭遞 蓋鬱醖鬱遞製壓鹹壓願 (膚繭鏇憲淵襯鏇夢繭範 ) | |||||||
N/A | - | 114 | 餘窪選範夢窪簾鏇鹽窪(積壓蓋顧憲淵範築鹽齋) = 膚觸積夢築網鏇築糧夢 醖壓淵憲齋醖築選觸鏇 (顧壓壓繭襯鹹蓋網鬱廠 ) 更多 | 积极 | 2013-11-05 | ||
餘窪選範夢窪簾鏇鹽窪(積壓蓋顧憲淵範築鹽齋) = 憲選壓構築範艱蓋遞鏇 醖壓淵憲齋醖築選觸鏇 (顧壓壓繭襯鹹蓋網鬱廠 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用